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Themicrotubule-associated protein tau is a principal component of neurofibril-
lary tangles, and has been identified as a key molecule in Alzheimer’s disease
and other tauopathies. However, it is unknown how a protein that is primarily
located in axons is involved in a disease that is believed to have a synaptic origin.
To investigate a possible synaptic function of tau, we studied synaptic plasticity
in the hippocampus and found a selective deficit in long-term depression (LTD)
in tau knockout mice in vivo and in vitro, an effect that was replicated by RNAi
knockdown of tau in vitro. We found that the induction of LTD is associated
with the glycogen synthase kinase-3-mediated phosphorylation of tau. These
observations demonstrate that tau has a critical physiological function in LTD.1. Introduction
The microtubule-associated protein ‘tau’ (MAPT) gene is located on chromosome
17 and consists of 16 exons [1]. Alternative splicing leads to six isoforms of tau, all
of which contain an amino-terminal projection domain and carboxy-terminalwith
microtubule-binding repeats [2]. Tau contains several critical serine and threonine
residues, the phosphorylation of which regulates its binding affinity for micro-
tubules [3,4]. It is believed that through this binding, tau has major roles in
stabilizing microtubules [5]. During neuronal development, tau expression is
increased in response to nerve growth factor [6], and subsequently enriched in
axons, a process that is required for maintaining axon morphology [7]. The
extent towhich taumay have additional functions unrelated to axonalmicrotubule
stabilization, however, is not known.
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ized by widespread accumulation of hyperphosphorylated
tau. Once hyperphosphorylated, tau is known to accumulate in
somatodendritic compartments and forms the core component
of neurofibrillary tangles (NFTs) [8]. It is generally believed that
hyperphosphorylation of tau is the critical step in causing it to
be missorted from the axon to dendrites, where it interferes
with neuronal function [9]. Associated with this accumula-
tion, there is a loss of synapses and eventually neurons [10,11].
However, the mechanism by which this occurs is unknown.
Increasing evidence suggests that in AD, synaptic dys-
function may initiate the cascades that result in cognitive
impairment and neurodegeneration. For example, it is well
established that oligomeric forms of b-amyloid (Ab) induce
a rapid alteration in synaptic plasticity, the process widely
believed to underlie learning and memory in the brain [12].
More specifically, Ab causes inhibition of long-term poten-
tiation (LTP) and enhancement of long-term depression
(LTD) in the hippocampus [13]. LTD involves the removal
of AMPA receptors (AMPARs) from synapses leading to a
reduction in synaptic efficiency, and can also result in the
shrinkage and elimination of synapses [14]. Therefore, a shift
in favour of LTDmay lead to neurodegeneration. That such pro-
cesses may be causally related to neurodegeneration in AD is
suggested by the finding that key molecules that are associated
with this disorder, such as glycogen synthase kinase (GSK)-3b
and caspase-3, are required for the induction of LTD in the hip-
pocampus [15–18] and mediate the Ab inhibition of LTP [19].
Interestingly, recent evidence has shown that Ab inhibition of
LTP is absent in the tau knockout (KO) mouse [20]. These
data, together with the observation that GSK-3b directly phos-
phorylates tau [15,18], suggest that tau may be a downstream
effector of GSK-3b in LTD. Therefore, we decided to examine
the role of tau in LTD in the hippocampus.
In this study, we found that in tau KO mice there is a loss
of LTD, whereas LTP is not affected. Furthermore, knock-
down of tau in hippocampal slices resulted in a complete
loss of LTD in the absence of any direct discernible effects
on synaptic transmission. We found that LTD was associated
with the phosphorylation of tau by GSK-3b [18]. Collectively,
these data suggest that tau phosphorylation is an essential
component of LTD.2. Results
(a) Long-term depression is absent in MAPTþ/ – and
MAPT – /– mice
The physiological role of tau in the hippocampus was initially
investigatedusing tauKOmice.We compared long-termsynap-
tic plasticity in adult (7–11 months old)MAPTþ/þ,MAPTþ/–
andMAPT –/– mice. Because the tau kinase GSK-3b is required
forLTD in thehippocampus [17], theprimary focusof our inves-
tigation was on this form of synaptic plasticity. Field excitatory
postsynaptic potentials (fEPSPs) were evoked in area CA1
of anaesthetized mice in response to electrical stimulation
of the ipsilateral Schaffer collateral–commissural pathway.
We found no differences in synaptic transmission between
MAPTþ/þ, MAPTþ/– and MAPT –/– mice, as assessed using
input–output curves (figure 1a), andweobservedno significant
differences in paired-pulse facilitation over a range of inter-
stimulus intervals (figure 1b). However, we found that whileLTD could be readily induced in adult MAPTþ/þ mice, it
was completely absent in MAPTþ/– and MAPT –/– mice
(figure 1c). By contrast, similar levels of LTP were observed in
the three genotypes (figure 1d). Therefore, tau is specifically
required for LTD in the hippocampus in vivo.
Next, we investigated LTD in acute brain slices from
young (14- to 17-day-old) mice. Consistent with the obser-
vations in vivo, LTD was absent in slices prepared from
MAPT2/2 mice but was readily induced in slices obtained
from MAPTþ/þ mice (figure 2a). We also investigated LTD
induced by a brief application of NMDA (25 mM, 3 min)
and found a specific deficit in slices from the MAPT –/–
mice (figure 2b). These results show that the LTD deficit
in MAPT –/– mice is apparent early in development and
therefore is not directly associated with ageing.
(b) Knockdown of tau by shRNA prevents long-term
depression induction
In these experiments, tau was absent or reduced throughout
the life of the animals, potentially leading to developmental
complications. Therefore, to investigate more directly whether
tau is involved in the LTD process, we used an shRNA probe
against rat tau and studied synaptic function in rat hippocam-
pal organotypic slice cultures (figure 3). To study the effects
of tau knockdown on synaptic transmission, simultaneous
recordings of excitatory postsynaptic currents (EPSCs) were
performed from tau-shRNA transfected and neighbouring
untransfected neurons. There were no significant differences
in AMPAR- and NMDA receptor (NMDAR)-mediated EPSCs
(EPSCA and EPSCN, respectively) between tau-shRNA trans-
fected cells and neighbouring untransfected neurons (EPSCA
in transfected cells, 252+12 pA; EPSCA in untransfected
cells, 253+18 pA, n ¼ 15 pairs, p. 0.05; EPSCN in transfected
cells, 256+16 pA; EPSCN in untransfected cells, 268+12 pA,
n ¼ 15 pairs, p. 0.05; figure 3a). We next investigatedwhether
tau-shRNA had any effect on LTD. Consistent with the LTD
experiments in MAPTþ/– and MAPT –/– mice, tau-shRNA
blocked LTD, whereas LTD was routinely induced in simul-
taneously recorded, neighbouring untransfected cells (tau-
shRNA transfected: 92+3% of baseline; untransfected: 63+
7%, n ¼ 5, p, 0.05, tau-shRNA versus control; figure 3b).
The blockof LTDwas a specific consequence of the knockdown
of endogenous tau, because expression of a non-effective,
scrambled tau-shRNA had no effect on LTD (61+7%, n ¼ 5,
p. 0.05, compared with control, figure 3c). Furthermore,
the tau-shRNA-mediated LTD deficit was rescued by co-
expression of human tau (60+4%, n ¼ 5, p. 0.05, compared
with control, figure 3d), which was resistant to knockdown
(rat tau-shRNA selectively reduces the expression of rat tau
but has no effect on human tau; data not shown). These find-
ings are consistent with our KO studies, confirming that tau
is required for LTD induction. Taken together, our data show
that tau is required for LTD across two species (rats and
mice) and in both juvenile and adult tissue.
(c) Tau is found in the postsynaptic compartment
The finding that tau is required for LTD is surprising since
LTD is generally considered to be mediated postsynaptically,
via the synaptic removal of AMPARs, whereas tau is present
primarily in axons. One possibility is that LTD causes the
redistribution of tau to dendritic shafts and/or spines. An
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Figure 1. Tau is required for LTD in vivo in mice. (a) No differences are shown in synaptic transmission between MAPTþ/þ, MAPTþ/2 and MAPT2/2 mice. The graph
plots the fEPSP amplitude versus the fibre volley (f.v.) amplitude (stimulus intensity range: 10–100 mA, grey dots). Input-output curves show regression (continuous
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MAPTþ/2: 96+ 3%; n ¼ 15; MAPT2/2: 98+ 2%; n ¼ 11; p, 0.001 in comparison with MAPTþ/þ mice, Bonferroni’s multiple comparison test). (d ) No differ-
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mally expressed in a postsynaptic compartment and it is
specifically this fraction that is involved in LTD. We explored
the latter possibility in two ways. First, we used immunogold
electron microscopy (EM) and compared the labelling of
tissue from MAPTþ/þ and MAPT –/– mice (figure 4a). We
could detect some immunoreactivity within dendritic spines
of the MAPTþ/þ, but not MAPT –/– , mice. Second, we
probed for the presence of tau, and another microtubule-
associated protein (MAP2), in microsome/organelle (P3),
cytoplasmic (S3) and synaptosomal (LP1) fractions prepared
from the hippocampus of MAPTþ/þ mice (figure 4b). As
expected, tau and MAP2 were recovered in the P3 fraction
and to a lesser extent in the S3 fraction. However, tau was
additionally detected in the LP1 fraction. Thus, a proportion
of tau is localized at a postsynaptic site where it could, in
principle, function directly in LTD.
Because GSK-3b is a major tau kinase [15,18,21] and is
activated during LTD [17], this seemed a likely candidate to
mediate the physiological phosphorylation of tau. We hypoth-
esized that the GSK-3bmediated phosphorylation of tau could
be an important regulator of LTD. If this is indeed the case, then
a prediction is that the induction of LTD should be associated
with an increase in the phosphorylation of tau. To investigate
this, we delivered low-frequency stimulation (LFS) and
measured the phosphorylation status of tau in the CA1 micro-
dissected dendritic region of rat hippocampal slices (figure 4c).
We observed a dramatic increase in the phosphorylation of tauusing PHF-1 ( p, 0.01, n ¼ 4, figure 4d,e), an antibody that
recognizes phosphorylation at residues Ser396 and Ser404
[22], but observed no difference following LFS in the total
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Figure 3. Knockdown of tau blocks LTD in rats. (a) Pairwise analysis of basal
synaptic transmission between rat tau-shRNA expressing and untransfected
neighbouring neurons, each obtained from independent slices. (b) Simul-
taneous dual-patch recordings were made from rat tau-shRNA-transfected
and untransfected neighbouring cells. LFS was delivered (at time indicated
by the bar) and LTD quantified 30 min later. (c) Data from scrambled tau-
shRNA transfected cells. (d ) Data from cells co-expressing rat tau-shRNA
and human tau. Error bars indicate s.e.m. (Online version in colour.)
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phorylation-independent anti-tau antibody [23]. We next
tested whether the phosphorylation of tau was due to
activation of GSK-3 during LTD by applying a highly selec-
tive GSK-3b inhibitor, CT-99021, during LFS (figure 4d). This
treatment eliminated the increase in tau phosphorylation
(figure 4d,e), while having no effect on the total levels of
tau (assessed using Tau-5; figure 4d,f ). Collectively, these
data demonstrate that LFS leads to the phosphorylation of
tau in a GSK-3b-dependent manner, further supporting
the idea that this phosphorylation event has a key role in the
induction of LTD.3. Discussion
In this study, we have provided several lines of complementary
evidence to suggest that tau is important for LTD in thehippocampus. First, we have shown that LTD at CA1 synapses
in vivo is not detectable in mice in which tau is absent or its
expression levels are reduced. Second, we found that LTD
was absent in slices acutely prepared from juvenile hippocam-
pal tissues of MAPT2/2 mice. Third, we have demonstrated
that knockdown of tau completely blocks LTD in organoty-
pic-cultured slices. Fourth, we have shown that LFS used to
elicit physiological LTD leads to enhanced phosphorylation of
tau at the PHF-1 epitope, via a GSK-3b-dependent mechanism.
It iswidely believed that tau, undernormal conditions, is pri-
marily involved in stabilizing microtubules in axons, and that
the dysregulation of this function somehow leads to neuronal
pathology [24]. The most prevalent form of such dysregulation
occurs through the hyperphosphorylation of tau, which is
involved in the generation of NFTs and plays a key role in
neurodegenerative conditions such as AD [25]. Hyperpho-
sphorylated tau is missorted to somatodendrites instead of
axons,where it is known to accumulate [26–28]. Suchmissorting
is assumed to contribute to neuronal pathology, because it pos-
itions tau where it can interfere directly with synaptic function.
How tau becomes missorted is not known.
An alternative possibility is that some tau is normally
present at synapses and it is this tau that is specifically associ-
ated with the neuropathology. Indeed, emerging evidence
suggests that tau may be present in dendrites even in the
absence of tauopathy [29] and that it could regulate interactions
between scaffolding proteins and signalling pathways in the
postsynaptic density (PSD) [30]. Furthermore, the localization
of tau within the postsynaptic complex can be affected by
NMDAR activation [31]. This raises an important question as
to what the physiological function of tau in dendrites might
be. Here, we have found, using both tau KO mice and RNAi
in organotypic slices prepared from rats, that tau is required
for LTD. This role is likely to be specific, because we found
no evidence that tau is required for maintaining normal synap-
tic transmission or for LTP. Previous work [9,32] has shown
that overexpression of tau may lead to inhibition of LTP.
Based on the present findings, we propose that this may be
because excess activation of tau induces a chronic form of
LTD that is manifest as an impairment in LTP.
We also found that LFS, a physiological LTD induction
protocol, resulted in the phosphorylation of tau and that
this was dependent on GSK-3. Thus, tau is most probably a
physiological substrate of GSK-3b during LTD. The next
key question concerns the physiological downstream effec-
tors of tau during LTD. At present, we can only speculate
on this issue. Because tau is a microtuble-associated pro-
tein, and because microtubules may be involved in LTD
[33], it is possible that tau is involved in the regulation of
LTD-dependent microtubule dynamics.
Tau can be divided into a projection domain (towards the
N-terminus, encompassing an acidic region and a proline-
rich region) and a microtubule-binding domain (towards the
C-terminus, including the microtubule-binding repeat region)
[34], each having specific roles in the regulation of tau function
[35,36]. Within these domains exist multiple regulatory sites of
phosphorylation on serine/threonine residues. Our findings
suggest a role in LTD for serine residues within the PHF
epitope (Ser396/404). Consistent with our findings, Mondra-
gon-Rodriguez et al. [31] recently reported a facilitation of
Ser396/404 phosphorylation following NMDA treatment. Cri-
tically, Ser396/404 residues can both be phosphorylated by
GSK-3b [37,38], an enzyme that is required for the induction
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potential GSK-3b phosphorylation sites on tau are phosphory-
lated during the physiological activation of this kinase. Our
finding that phosphorylation of Ser396/404 following LFS is
prevented by CT-99021 demonstrates that GSK-3b is upstream
of tau in LTD and that this particular phosphorylation event
probably has a physiological function.4. Conclusion
We have shown that tau is required for NMDAR-dependent
LTD is the hippocampus. Our data suggest a model wherebyduring LTD, activation of GSK-3b leads to phosphorylation
of tau and this promotes LTD.5. Methods
(a) In vivo electrophysiology
MaleC57/BL6Jmicewereused forall comparativeKOexperiments.
MAPT2/2 and MAPTþ/2 mice were maintained by backcrossing
with C57/BL6J mice. Mice were individually housed and kept on
a 12 h light/dark schedule. All mice had free access to food and
water. Each mouse was anaesthetized with 3% isoflurane–air mix-
ture, and fixed in a stereotaxic device (model 900, David Kopf
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electrode (two enamel-coated wires with 10 mm diameter and
200 kV impedance) was positioned into stratum radiatum of the
left hippocampal CA1 area (21.7 mm from bregma, 1.65 mm from
medial, 1.3 mm depth) and a mono-polar recording electrode
(0.5–1 MV) was placed 200 mm posterior to the stimulating
electrode. The animal was maintained anaesthetized (1.5% isoflur-
ane–air mixture) for at least 3 h (body temperature was kept at
368C). For the fEPSPmeasurements, the electrical signal was ampli-
fied 100 times (ER-1, Cygnus Technology, USA), digitized (Digidata
1321A,Axon Instruments, FosterCity,CA,USA)andprocessedona
computer. To induce LTP, 100 pulses at 100 Hz were applied three
times (at 180 s intervals), and to induce LTD, 900 pulses at 1 Hz
were delivered. The amplitude and slope of each recorded fEPSP
wasmeasured by a custom application based onMATLAB (version
8,Mathworks Inc., CA, USA). fEPSPs were analysed only when the
maximal amplitudewasover 1 mV, and the latencyof theminimum
peak from stimulus was shorter than 7 ms. Experiments were
performed blindly.
(b) In vitro electrophysiology
For in vitro electrophysiology experiments, acute hippocampal
slices were obtained from P24 to P28 male Wistar rats or
MAPT2/2 and MAPTþ/2 mice. Animals were sacrificed by dis-
location of the neck and then decapitated. The brain was rapidly
removed and placed in ice-cold artificial cerebrospinal fluid
(aCSF) containing (in mM): NaCl 124, KCl 3, NaHCO3 26,
NaH2PO4 1.25, CaCl2 2, MgSO4 1 and D-glucose 10 (bubbled
with 95% O2/5% CO2). Transverse hippocampal slices (400 mm
thick) were prepared using a McIllwain tissue chopper (Mickle
Laboratory Engineering Co. Ltd., Gomshall, UK). Hippocampal
slices were stored in aCSF (20–258C) for 1–2 h before transfer-
ring to the recording chamber, in which they were submerged
in aCSF (308C) flowing at 2 ml min21. Extracellular field poten-
tials were recorded in the CA1 region using glass electrodes
containing NaCl (3 M). A stimulating electrode in CA2 was
used to evoke field EPSPs (constant voltage, 100 ms duration,
repeated at 30 s intervals). The slope of the evoked fEPSP was
measured and expressed relative to the normalized precondition-
ing baseline. Data were captured and analysed using WINLTP
(www.winltp.com). Experiments in which changes in the fibre
volley occurred were discarded.
(c) Hippocampal slice culture
Hippocampal slice cultures were prepared from 6- to 7-day-old
male Wistar rats, as previously described [19]. Whole-cell patch
clamp recordings of CA1 neurons transfected with shRNA plas-
mids were made 3–4 days following transfection. Using a
biolistic Gene Gun (BioRad, USA), neurons were transfected
with plasmids expressing shRNA against rat tau protein (OriGene
Technologies, MD, USA). A mixture of four different tau (0N/3R,
0N/4R, 1N/4R and 2N/4R) shRNA constructs (1 : 1 : 1 : 1, in
pGFP-V-RS vector) were used for tau silencing. A non-effective
scrambled sequence shRNAwas used as a negative control against
tau-shRNA. EPSCs were recorded using a multi-clamp 700B
amplifier (Axon Instruments). Recordingswere carried out in a sol-
ution containing (in mM): NaCl 119, KCl 2.5, CaCl2 4, MgCl2 4,
NaHCO3 26, NaH2PO4 1, glucose 11, picrotoxin 0.02 and 2-chlor-
oadenosine 0.01, gassed with 5% CO2/95% O2, at pH 7.4. To
induce LTD, 200 pulses at 1 Hz were delivered at a holding poten-
tial of 240 mV. AMPAR-mediated EPSC amplitude (EPSCA) was
determined as the peak EPSC amplitude at a holding potential
of 270 mV. NMDAR-mediated EPSC amplitude (EPSCN) was
determined 50–70 ms after the EPSCA peak at a holding potential
of þ40 mV. In some experiments, dual patch clamp recordings
were made simultaneously from a pair of neighbouring CA1 pyr-
amidal neurons, one transfected and the other untransfected.n values indicate number of cells, each obtained from independent
slices. Error bars indicate s.e.m.
(d) Tau constructs
0N3R and 2N4R human tau cDNAs were framed in pEGFP-C1
host vectors (Clontech, Mountain View, CA, USA), and provided
by Drs R. Brandt (University of Ostanbru¨ck, Germany) and
S. Lovestone (King’s College, UK).
(e) Immunogold electron microscopy
Under deep pentobarbital anaesthesia, animals were perfused
with 4% paraformaldehyde in 0.1 M cacodylate buffer (CB, pH
7.4). After further fixation of the brain at 48C overnight, 300-mm-
thick hippocampal slices were made. After incubation with block-
ing solution (5% normal goat serum in 0.1 M CB) for 1 h at room
temperature, the slices were incubated with primary anti-tau anti-
body, JM (rabbit, 1 : 300), at 48C for 2 days, followed bya secondary
anti-rabbit IgG conjugatedwith FITC-gold (goat, Nanoprobes,NY,
USA, 1 : 100) overnight. The slices were re-fixed with a mixture of
2.5% glutaraldehyde and 1% tannic acid at 48Covernight. The gold
signal enhancement procedure was performed according to
the manufacturer’s instruction (GoldEnhance-EM, Nanoprobes).
After the osmication of slices (1% OsO4–1.5% potassium
ferrocyanide in 0.1 M CB) at 48C for 10 min, the slices were
dehydrated, and embedded in epoxy resin. The stratum radiatum
of CA1 region was examined electron microscopically (JEM-
1200EX, JEOL, Japan) after metal-staining using uranium acetate
and lead citrate.
( f ) Subcellular fractionation
Partial subcellular fractionation was performed on mouse hippo-
campus basically according to a previous report [39]. Postnuclear
supernatant was subjected to centrifugation (12 500g), and divided
into the crude synaptosomal fraction and synaptosome-depleted
fraction. The crude synaptosomal fraction was further purified
by hypotonic lysis and centrifugation (25 000g), and the resul-
tant pellet was the PSD-95-rich synaptosome fraction (LP1). The
synaptosome-depleted fraction was further subjected to ultracen-
trifugation (100 000g), and separated to the microsome fraction
(P3) and cytoplasm fraction (S3). We used the following antibodies
for experiments: NeuN, mouse monoclonal (Millipore; 1 : 1000)
Tau-5, mouse monoclonal (Invitrogen; 1 : 500); PSD-95 (Millipore;
1 : 1000) and MAP2 (Millipore; 1 : 1000).
(g) Low-frequency stimulation, microdissection and
western blotting
Rat hippocampal slices fromP24 toP28were subjected to a standard
1 Hz, 900 pulses, LFS protocol (stimulation set at a predetermined
intensity; 70%of themaximal fEPSPamplitudevoltage stimulation),
using a bipolar stimulation electrode, in the presence or absence of
CT-99021 (1 mM). The dendritic CA1 region was then immediately
dissected and snap frozen. Samples were lysed and SDS–PAGE
was performed as previously shown [19]. PHF1 monoclonal anti-
body (kindly provided by Dr Peter Davies) was used at 1 : 1000
for western blot. Optical densities of immunoreactive bands were
quantified using NIH IMAGEJ software (downloaded from http://
rsb.info.nih.gov/ij/). n indicates the number of independent
experiments from different animals.
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